Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving hundreds of leading biopharmaceutical companies globally:

US Army
UBS
Johnson and Johnson
Harvard Business School
Boehringer Ingelheim
Dow
Colorcon
Medtronic
Cipla

Generated: April 22, 2018

DrugPatentWatch Database Preview

Details for Patent: 7,981,877

« Back to Dashboard

Which drugs does patent 7,981,877 protect, and when does it expire?

Patent 7,981,877 protects LOCOID and is included in one NDA.
Summary for Patent: 7,981,877
Title:Stabilized steroid composition and method for its preparation
Abstract: Stabilized, 17-substituted hydrocortisone containing compositions and methods of manufacture are disclosed. Isomerization of the hydrocortisone component of topical steroid compositions is markedly reduced by including an omega-6 acid component in the form of a free acid or as a compound such as an ester. Specifically disclosed are methods for preventing the isomerization of hydrocortisone 17-butyrate into hydrocortisone 21-butyrate through the use of safflower oil.
Inventor(s): Patel; Pravin M. (Bloomfield Hills, MI)
Assignee:
Application Number:11/432,742
Patent Claim Types:
see list of patent claims
Use; Composition;

Drugs Protected by US Patent 7,981,877

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Patent Submitted
Precision Dermat LOCOID hydrocortisone butyrate LOTION;TOPICAL 022076-001 May 18, 2007 AB RX Yes Yes ➤ Sign Up ➤ Sign Up Y ➤ Sign Up
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Patent Submitted

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

Non-Orange Book US Patents Family Members for Patent 7,981,877

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
8,546,364 Stabilized steroid composition and method for its preparation ➤ Sign Up
7,378,405 Stabilized steroid composition and method for its preparation ➤ Sign Up
8,389,502 Stabilized steroid composition and method for its preparation ➤ Sign Up
Patent No. Title Estimated Patent Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

Cipla
McKesson
Fuji
Deloitte
US Department of Justice
Citi
Daiichi Sankyo
Chubb
Accenture

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.